retatrutide phase 2 nejm 2023 weight loss percent 48 weeks 🚨 Today, retatrutide, the GIP/GLP-1/glucagon triple agonist, just delivered TRIUMPH-2 top-line results. A study in those with concurrent obesity and type diabetes. 📊 Mean body change at 80 weeks: ⬇️ Phase 2 Trial of Retatrutide

Prior authorization denials happen frequently, forcing patients to either appeal for weeks or seek alternatives that don't depend on insurance intermediaries

But if its been more than 5 days since your missed dose, skip the missed dose and go back to your regular dosing schedule

Patients experiencing persistent skin dryness, unusual texture changes, or delayed wound healing should discuss nutritional assessment with their healthcare provider, though a direct causal relationship between GLP-1 therapy and specific nutritional deficiencies has not been firmly established

Pregnant and breastfeeding women are generally advised against using Semaglutide, as its safety during pregnancy has not been established

Starting with lower GLP-1 doses and gradually adapting to the ketogenic diet may improve tolerance

They are also the number one reason people botch the tirzepatide to retatrutide transition